Found 544 hits.
| 152 | Türk, M., Carneiro-Leão, L., Kolkhir, P., Bonnekoh, H., Buttgereit, T., and Maurer, M.+: How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J. Allergy Clin. Immunol. Pract. 2020: 8; 115-124. IF: 8.86 |
r.152
| 204 | Saini, S. S., Bindslev-Jensen, C., Maurer, M. Grob, J.-J., Baskan, E. B., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., Spector, S., and Rosén, K.+: Efficacy and safety of Omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: A randomized, placebo-controlled study. J. Invest. Dermatol. 2015: 135; 67-75. IF: 6.91 |
| 33 | Peters, E. M., Maurer, M. Botchkarev, V. A., deMasey Jensen, K., Welker, P., Scott, G. A., and Paus, R.+: Kit is expressed by epithelial cells in vivo. J. Invest. Dermatol. 2003: 121; 976-984. IF: 4.19 |
| 53 | Siebenhaar, F., Kühn, W., Zuberbier, T., and Maurer, M.+: Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J. Allergy Clin. Immunol. 2007: 120; 213-215. IF: 8.12 |
|
551. |
Siebenhaar, F., Altrichter, S., Bonnekoh, H., Hawro, T., Hawro, M., Michaelis, E. G., Kantor, A. M., Chang, A. T., Youngblood, B. A., Sing, B., Rasmussen, H. S., and Maurer, M.+: Safety and efficacy of Lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. Brit. J. Dermatol. 2023: 189; 511-519. IF: 11.00 |
o.551
|
476. |
Luo, Y., Fernandez Vallone, V., Frischbutter, S., Stachelscheid, H., Streu-Haddad, V., He, J., Maurer, M.+, Siebenhaar, F.*, and Scheffel, J.+*: A novel approach for studying mast cell-driven disorders: mast cells derived from induced pluripotent stem cells. J. Allergy Clin. Immunol. 2022: 149; 1060-1068. IF: 14.20 |
o.476
|
555. |
Xiang, Y.-K., Kolkhir, P., Scheffel, J., Sauer, M., Vera, C., Frischbutter, S., Krause, K., Siebenhaar, F., Metz, M., Maurer, M.+, and Altrichter, S.: Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. J. Allergy Clin. Immunol. Pract. 2023: 11; 2417-2425. IF: 8.20 |
|
441. |
Metz, M., Altrichter, S., Buttgereit, T., Fluhr, J. W., Fok, J. S., Hawro, T., Jiao, Q., Kolkhir, P., Krause, K., Magerl, M., Pyatilova, P., Siebenhaar, F., Su, H., Terhorst-Molawi, D., Weller, K., Xiang, Y.-K., and Maurer, M.+: The diagnostic workup in chronic spontaneous urticaria – what to test and why. J. Allergy Clin. Immunol. Pract. 2021: 9; 2274-2283. IF: 11.02 |
o.441
|
480. |
Altrichter, S., Staubach, P., Pasha, M., Sing, B., Chang, A. T., Bernstein, J. A., Rasmussen, H. S., Siebenhaar, F., and Maurer, M.+: An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J. Allergy Clin. Immunol. 2022: 149; 1683-1690. IF: 14.20 |
o.480
|
444. |
Hackler, Y., Siebenhaar, F., Löhning, M., Maurer, M., and Muñoz, M.+: Mast cells modulate antigen-specific CD8+ T cell activation during LCMV infection. Front. Immunol. 2021: 12; 688347. IF: 8.79 |
o.444